QQQ vs XBI
Invesco QQQ Trust vs SPDR S&P Biotech ETF
- • QQQ has the lower expense ratio at 0.18% vs 0.35% for XBI.
- • QQQ pays a higher dividend yield (0.42%).
Side-by-side metrics
| Metric | QQQ | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.18% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.42% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $440.26B | $8.30B |
YTD return | 13.40% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.18 | 1.09 |
P/E ratio | 33.90 | — |
Last price | $694.94 | $133.66 |
Inception | — | — |
Issuer | Invesco | State Street |
QQQ top holdings
| NVDA | NVIDIA Corp | 8.53% |
| AAPL | Apple Inc | 7.01% |
| MSFT | Microsoft Corp | 5.33% |
| AMZN | Amazon.com Inc | 5.01% |
| GOOGL | Alphabet Inc Class A | 3.94% |
| GOOG | Alphabet Inc Class C | 3.65% |
| AVGO | Broadcom Inc | 3.48% |
| TSLA | Tesla Inc | 3.35% |
| META | Meta Platforms Inc Class A | 3.18% |
| WMT | Walmart Inc | 3.13% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About QQQ
QQQ (Invesco QQQ Trust) is Tracks the Nasdaq-100, heavy in mega-cap tech. Managed by Invesco, the fund carries $440.3B in assets under management, an expense ratio of 0.18%, a dividend yield of 0.42%. Its largest holding is NVIDIA Corp (NVDA), which represents 8.5% of the portfolio. Real Estate is the fund's largest sector exposure at 0.1%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.